Patients who subsequently test negative for MG-specific autoantibodies may still be considered positive for autoantibodies against MuSK or AChR, and show a response to immunotherapy.34 This may explain why all five of the patients in this group who received rozanolixizumab were MG-ADL responders. This evidence concerns the gene MUSK and myasthenia gravis.